252 related articles for article (PubMed ID: 35467312)
21. Cost-Effectiveness Analysis of Ezetimibe as the Add-on Treatment to Moderate-Dose Rosuvastatin versus High-Dose Rosuvastatin in the Secondary Prevention of Cardiovascular Diseases in China: A Markov Model Analysis.
Yang H; Li N; Zhou Y; Xiao Z; Tian H; Hu M; Li S
Drug Des Devel Ther; 2020; 14():157-165. PubMed ID: 32021100
[TBL] [Abstract][Full Text] [Related]
22. Cost-Effectiveness of Alirocumab: A Just-in-Time Analysis Based on the ODYSSEY Outcomes Trial.
Kazi DS; Penko J; Coxson PG; Guzman D; Wei PC; Bibbins-Domingo K
Ann Intern Med; 2019 Feb; 170(4):221-229. PubMed ID: 30597485
[TBL] [Abstract][Full Text] [Related]
23. Inclisiran as Adjunct Lipid-Lowering Therapy for Patients with Cardiovascular Disease: A Cost-Effectiveness Analysis.
Kam N; Perera K; Zomer E; Liew D; Ademi Z
Pharmacoeconomics; 2020 Sep; 38(9):1007-1020. PubMed ID: 32789593
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness and Budget Impact of Treatment with Evolocumab Versus Statins and Ezetimibe for Hypercholesterolemia in Spain.
Olry de Labry Lima A; Gimeno Ballester V; Sierra Sánchez JF; Matas Hoces A; González-Outón J; Alegre Del Rey EJ
Rev Esp Cardiol (Engl Ed); 2018 Dec; 71(12):1027-1035. PubMed ID: 29937273
[TBL] [Abstract][Full Text] [Related]
25. Design and rationale of the GAUSS-2 study trial: a double-blind, ezetimibe-controlled phase 3 study of the efficacy and tolerability of evolocumab (AMG 145) in subjects with hypercholesterolemia who are intolerant of statin therapy.
Cho L; Rocco M; Colquhoun D; Sullivan D; Rosenson RS; Dent R; Xue A; Scott R; Wasserman SM; Stroes E
Clin Cardiol; 2014 Mar; 37(3):131-9. PubMed ID: 24477778
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of adding ezetimibe and/or PCSK9 inhibitors to high-dose statins for secondary prevention of cardiovascular disease in Chinese adults.
Xiang Y; Gan L; Du H; Hao Q; Aertgeerts B; Li S; Hu M
Int J Technol Assess Health Care; 2023 Aug; 39(1):e53. PubMed ID: 37650314
[TBL] [Abstract][Full Text] [Related]
27. Lipid-lowering treatment up to one year after acute coronary syndrome: guidance from a French expert panel for the implementation of guidelines in practice.
Sabouret P; Puymirat E; Kownator S; Abdennbi K; Lebeau F; Meltz M; Angoulvant D; Schiele F
Panminerva Med; 2023 Jun; 65(2):244-249. PubMed ID: 36222543
[TBL] [Abstract][Full Text] [Related]
28. Cost-Effectiveness Analysis of Non-Statin Lipid-Modifying Agents for Secondary Cardiovascular Disease Prevention Among Statin-Treated Patients in Thailand.
Kongpakwattana K; Ademi Z; Chaiyasothi T; Nathisuwan S; Zomer E; Liew D; Chaiyakunapruk N
Pharmacoeconomics; 2019 Oct; 37(10):1277-1286. PubMed ID: 31243736
[TBL] [Abstract][Full Text] [Related]
29. Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Wilson PWF; Polonsky TS; Miedema MD; Khera A; Kosinski AS; Kuvin JT
Circulation; 2019 Jun; 139(25):e1144-e1161. PubMed ID: 30586775
[TBL] [Abstract][Full Text] [Related]
30. Systematic Review and Network Meta-Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia.
Toth PP; Worthy G; Gandra SR; Sattar N; Bray S; Cheng LI; Bridges I; Worth GM; Dent R; Forbes CA; Deshpande S; Ross J; Kleijnen J; Stroes ESG
J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 28971955
[TBL] [Abstract][Full Text] [Related]
31. 2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.
Lloyd-Jones DM; Morris PB; Ballantyne CM; Birtcher KK; Daly DD; DePalma SM; Minissian MB; Orringer CE; Smith SC
J Am Coll Cardiol; 2017 Oct; 70(14):1785-1822. PubMed ID: 28886926
[TBL] [Abstract][Full Text] [Related]
32. Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States.
Gandra SR; Villa G; Fonarow GC; Lothgren M; Lindgren P; Somaratne R; van Hout B
Clin Cardiol; 2016 Jun; 39(6):313-20. PubMed ID: 27092712
[TBL] [Abstract][Full Text] [Related]
33. Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events.
Zhan S; Tang M; Liu F; Xia P; Shu M; Wu X
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012502. PubMed ID: 30480766
[TBL] [Abstract][Full Text] [Related]
34. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
Sahebkar A; Watts GF
Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
[TBL] [Abstract][Full Text] [Related]
35. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
Jellinger PS; Handelsman Y; Rosenblit PD; Bloomgarden ZT; Fonseca VA; Garber AJ; Grunberger G; Guerin CK; Bell DSH; Mechanick JI; Pessah-Pollack R; Wyne K; Smith D; Brinton EA; Fazio S; Davidson M
Endocr Pract; 2017 Apr; 23(Suppl 2):1-87. PubMed ID: 28437620
[TBL] [Abstract][Full Text] [Related]
36. Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Wilson PWF; Polonsky TS; Miedema MD; Khera A; Kosinski AS; Kuvin JT
J Am Coll Cardiol; 2019 Jun; 73(24):3210-3227. PubMed ID: 30423394
[TBL] [Abstract][Full Text] [Related]
37. Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial.
Giugliano RP; Keech A; Murphy SA; Huber K; Tokgozoglu SL; Lewis BS; Ferreira J; Pineda AL; Somaratne R; Sever PS; Pedersen TR; Sabatine MS
JAMA Cardiol; 2017 Dec; 2(12):1385-1391. PubMed ID: 29117276
[TBL] [Abstract][Full Text] [Related]
38. PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations.
Hao Q; Aertgeerts B; Guyatt G; Bekkering GE; Vandvik PO; Khan SU; Rodondi N; Jackson R; Reny JL; Al Ansary L; Van Driel M; Assendelft WJJ; Agoritsas T; Spencer F; Siemieniuk RAC; Lytvyn L; Heen AF; Zhao Q; Riaz IB; Ramaekers D; Okwen PM; Zhu Y; Dawson A; Ovidiu MC; Vanbrabant W; Li S; Delvaux N
BMJ; 2022 May; 377():e069066. PubMed ID: 35508320
[TBL] [Abstract][Full Text] [Related]
39. Projected cost-effectiveness of ezetimibe/simvastatin compared with doubling the statin dose in the United Kingdom: findings from the INFORCE study.
Reckless J; Davies G; Tunceli K; Hu XH; Brudi P
Value Health; 2010; 13(6):726-34. PubMed ID: 20561328
[TBL] [Abstract][Full Text] [Related]
40. Additive effects of ezetimibe, evolocumab, and alirocumab on plaque burden and lipid content as assessed by intravascular ultrasound: A PRISMA-compliant meta-analysis.
Liang D; Li C; Tu Y; Li Z; Zhang M
Medicine (Baltimore); 2022 Oct; 101(41):e31199. PubMed ID: 36254013
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]